1,2-Dihydroquinoline-4-carbonitrile | 859779-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,2-Dihydroquinoline-4-carbonitrile
• CAS: 859779-38-7
• 化学式: C₁₀H₈N₂
• 分子量: 156.18
• InChiKey: CYUMUIUFNYKKMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS
  申请人：ORION CORPORATION

  公开号：US20160368906A1

  公开（公告）日：2016-12-22

  The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Cy 1 , Cy 2 , X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.

  本公开提供了公式（I）的双环杂环衍生物，可能在治疗上有用，更具体地作为溴结构域抑制剂；（I）中，R1、R2、R3、R4、L1、L2、Cy1、Cy2、X、n和虚线具有规范中给定的相同含义，以及其在治疗和预防疾病或疾病中有用，特别是在与溴结构域抑制剂相关的疾病或疾病中的使用。本公开还提供了制备化合物和包括至少一种公式（I）的双环杂环衍生物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• [EN] 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML)<br/>[FR] 4-ANILINO-3-QUINOLINECARBONITRILES DESTINES AU TRAITEMENT DE LEUCEMIE MYELOGENE CHRONIQUE (CML)
  申请人：WYETH CORP

  公开号：WO2005047259A1

  公开（公告）日：2005-05-26

  Compounds of the formula (I): wherein: n is an integer from 0-3; X is N, CH; R is alkyl of 1 to 3 carbon atoms; R' is 2,4-diCl, 5-OMe in para, ortho, or meta position; 2,4-diCl in para position; 3,4,5­tri-OMe in para position; 2-Cl, 5-OMe in para position; 2-Me, 5-OMe in para position; 2,4-di-Me in para position; 2,4-diMe-5-OMe in para position; 2,4-diCl, 5-OEt in para position; and R2 is alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof.

  式(I)的化合物：其中：n是0-3之间的整数；X是N，CH；R是1至3个碳原子的烷基；R'是对位、邻位或间位的2,4-二氯，5-甲氧基；对位的2,4-二氯；对位的3,4,5-三甲氧基；对位的2-氯，5-甲氧基；对位的2-甲基，5-甲氧基；对位的2,4-二甲基；对位的2,4-二甲基-5-甲氧基；对位的2,4-二氯，5-乙氧基；以及R2是1至3个碳原子的烷基，及其药用可接受的盐。
• [EN] INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLE/PYRZOLO[4,3-C]PYRIDINE UTILISÉS COMME INHIBITEURS DE JNK, COMPOSITIONS ET MÉTHODE S'Y RAPPORTANT ET PRODUITE INTERMÉDIAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2004113303A1

  公开（公告）日：2004-12-29

  The present invention relates to new compounds of formula (I) in which:X is CR4 or N; R1 is -OR5, -NHCOR6 or -NR6R7; R2 is hydrogen, Oar1 or -NHAr1 wherein Ar1 is aryl optionally substituted with one or more of R8, -OR8, -NR8R9, -CONR8R9, -COOR8, -NR8COR9, -SR8, -SO2NR8R9, -NR8SO2 R9, halogen, cyano, or nitro; R3 is hydrogen or -NHAr2 wherein Ar2 is benzene optionally substituted with one or more of R8, -OR8, -NR8R9, halogen or nitro, wherein R2 and R3 is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式（I）的新化合物，其中：X为CR4或N；R1为-OR5，-NHCOR6或-NR6R7；R2为氢，Oar1或-NHAr1，其中Ar1是芳基，可选择地取代一个或多个R8，-OR8，-NR8R9，-CONR8R9，-COOR8，-NR8COR9，-SR8，-SO2NR8R9，-NR8SO2R9，卤素，氰基或硝基；R3为氢或-NHAr2，其中Ar2是苯，可选择地取代一个或多个R8，-OR8，-NR8R9，卤素或硝基，其中R2和R3不同时为氢；一种制备它们的方法和在其中使用的新中间体，含有所述治疗活性化合物的制药配方以及所述活性化合物在治疗中的使用。
• [EN] 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY<br/>[FR] 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALCOXY-3-QUINOLINECARBONITRILES POUR LE TRAITEMENT DES LESIONS ISCHEMIQUES
  申请人：WYETH CORP

  公开号：WO2004075898A1

  公开（公告）日：2004-09-10

  Compounds of the Formula (I), wherein X is N, CH n is an integer from 1-3; and R' and R are independently, alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof, with the proviso that when n is 1, X is not N; are useful for inhibiting vascular permeability caused by disease, injury, or other trauma.

  公式（I）的化合物，其中X为N，CHn为1-3的整数；R'和R分别独立地表示1到3个碳原子的烷基，以及其药学上可接受的盐，但当n为1时，X不是N。这些化合物可用于抑制疾病、损伤或其他创伤引起的血管通透性。
• [EN] PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES<br/>[FR] PREPARATION DE 3-QUINOLINE ET DE 3-QUINOL- 4-ONE CARBONITRILES SUBSTITUES EN POSITION 7
  申请人：WYETH CORP

  公开号：WO2003093241A1

  公开（公告）日：2003-11-13

  There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile is converted in three steps to 7-substituted-3-quinolinecarbonitriles which inhibit the action of certain protein kinases and are useful in the treatment of cancer.

  提供了一种制备7-取代-3-喹啉羰基腈及其中间体的方法，该中间体可用于制备7-取代-3-喹啉羰基腈及其药用可接受盐的方法。其中，7-氟-4-氧代-1,4-二氢-3-喹啉羰基腈经过三步转化成为抑制某些蛋白激酶作用且用于治疗癌症的7-取代-3-喹啉羰基腈。